Endeavor BioMedicines Stock

endeavorbiomedicines.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $163MM

Endeavor BioMedicines is a biotechnology company that is striving to discover new ways to treat patients who have life-threatening diseases. The company is working toward that goal by aiming to combat the drivers of fibrosis and oncology, which are both areas of medicine that have unmet needs. Endeavor BioMedicines was founded in 2018 by John Hood and Miguel de los Rios and is headquartered in San Diego, CA. In addition to looking for treatments that alleviate symptoms, Endeavor BioMedicines is seeking ways to reverse the effects of terminal illnesses.

Register To Buy and Sell Shares

For more details on financing and valuation for Endeavor BioMedicines, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Endeavor BioMedicines’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Endeavor BioMedicines.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Endeavor BioMedicines investors also invested in these private companies

Matrix Capital Management
Silver Arch Bio
Velosity Capital

Team

Management Team

John Hood Ph.D
Co-Founder & Chief Executive Officer
Miguel de los Rios Ph.D
Co-Founder, President & Chief Scientific Officer
Vishaal Turakhia
Chief Financial Officer
Chris Krueger
Chief Operating Officer
Paul Frohna MD
Chief Medical Officer
Enoch Kariuki
President

Board Members

Andrew Lam
Ally Bridge Group
Bernard Davitian
Omega Funds
Brian Liu MD
Longitude Capital
Cindy Wang Ph.D
Longitude Capital
Karan Takhar
Matrix Capital Management
Monal Mehta Ph.D
Avidity Partners
Noelle Hutchins Ph.D
Omega Funds
Otello Stampacchia Ph.D
Omega Funds
Patrick Enright
Longitude Capital

Frequently Asked Questions About Endeavor BioMedicines’ Stock

plusminus
Can you buy Endeavor BioMedicines’ stock?
Endeavor BioMedicines is not publicly traded on NYSE or NASDAQ in the U.S. To buy Endeavor BioMedicines’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Endeavor BioMedicines’ stock?
Yes, you can sell stock of a private company like Endeavor BioMedicines. Forge can help you sell your Endeavor BioMedicines stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Endeavor BioMedicines’ stock price?
Endeavor BioMedicines is a privately held company and therefore does not have a public stock price. However, you may access Endeavor BioMedicines’ private market stock price with Forge Data.
plusminus
What is Endeavor BioMedicines’ stock ticker symbol?
Endeavor BioMedicines does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Endeavor bags $132.5M series C, extending runway for clinical-stage fibrosis drugs through 2026
In series C funding led by new investors such as AyurMaya, Endeavor raised $132.5 million.
Updated on: May 18, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.